Illumina, Inc. (ILMN) Stake Boosted by Salem Investment Counselors Inc.
Salem Investment Counselors Inc. grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 28.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,474 shares of the life sciences company’s stock after acquiring an additional 1,675 shares during the period. Salem Investment Counselors Inc.’s holdings in Illumina were worth $2,242,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of ILMN. Vanguard Group Inc raised its stake in Illumina by 1.8% in the third quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after buying an additional 188,516 shares in the last quarter. Oregon Public Employees Retirement Fund raised its stake in Illumina by 66,581.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after buying an additional 10,546,495 shares in the last quarter. Jennison Associates LLC raised its stake in Illumina by 13.5% in the fourth quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after buying an additional 653,348 shares in the last quarter. Capital International Investors bought a new position in Illumina in the third quarter worth about $1,482,837,000. Finally, Geode Capital Management LLC raised its stake in Illumina by 10.1% in the fourth quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after buying an additional 170,046 shares in the last quarter. 90.37% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Francis A. Desouza sold 3,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $316.51, for a total transaction of $949,530.00. Following the sale, the insider now owns 79,346 shares in the company, valued at $25,113,802.46. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert S. Epstein sold 1,000 shares of the stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $280.11, for a total transaction of $280,110.00. Following the sale, the director now owns 4,256 shares in the company, valued at approximately $1,192,148.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,526 shares of company stock worth $10,501,041. Corporate insiders own 0.54% of the company’s stock.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.04). Illumina had a net margin of 24.79% and a return on equity of 24.51%. The firm had revenue of $867.00 million for the quarter, compared to analysts’ expectations of $865.33 million. During the same quarter in the previous year, the company earned $1.44 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Illumina, Inc. will post 6.53 earnings per share for the current year.
A number of brokerages have weighed in on ILMN. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $347.00 price objective on the stock in a report on Friday, January 11th. Morgan Stanley cut their price objective on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a report on Monday, January 7th. Deutsche Bank cut shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective on the stock. in a report on Friday, January 25th. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $340.00 to $370.00 in a report on Thursday, January 3rd. Finally, BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Wednesday, February 13th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Illumina currently has an average rating of “Buy” and an average price target of $345.82.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/illumina-inc-ilmn-stake-boosted-by-salem-investment-counselors-inc/2919297.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Call Option
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.